COMPANY PROFILE / iPS CELLS & REGENERATIVE MEDICINE
Orca Bio
A cell therapy company that reached its first FDA approval by sorting donor cells to high purity, with neither iPS cells nor gene editing
Orca Bio (legal name Orca Biosystems, Inc.) is a cell therapy company that sorts the cells used in haematopoietic stem cell transplants for blood cancers out of donor blood to a high degree of purity, then assembles them patient by patient and delivers them. On 30 June 2026 the FDA approved its first product, TREGZI (Orca-T). Seen from the iPS cell and regenerative medicine side, it is the endpoint of a different route: precisely engineering the composition of donor-derived cells, using neither iPS cells nor gene editing. Orca Bio is unlisted and does not publish its financials, so this profile relies only on FDA approval documents, the company's official announcements, peer-reviewed papers and clinical trial registrations. It is not medical advice on treatment choices.
- Orca Bio in 30 seconds, and where it stands in iPS cells and regenerative medicine
- The logo and how the name is written
- Where the company sits in the iPS cell and regenerative medicine landscape
- Scale (an unlisted company)
- Resources committed to the field
- Track record so far
- Plans ahead
- What the company is aiming for
- Partnership map
- The technologies and products it offers
- The risks this company carries
- Glossary, references and claim-to-source audit
1. Orca Bio in 30 seconds, and where it stands in iPS cells and regenerative medicine
California, U.S.Manufacturing site in Sacramento, California
Companies involved in iPS cells and regenerative medicine fall into three broad groups: large pharma & strategic partners, genome editing & gene therapy, and iPS cell & cell therapy. Orca Bio is a cell therapy company, but what it handles is neither iPS cells nor gene-edited cells. Its therapy is made from the blood of a healthy donor: haematopoietic stem cells, regulatory T cells (Treg) and conventional T cells (Tcon) are each sorted to high purity and mixed in fixed ratios for each patient Sourced. On 30 June 2026 the FDA approved TREGZI (nonproprietary name allogeneic regulatory T cell immunotherapy with HSPC and T cells-vldq; known clinically as Orca-T), and the company became a company with an approved product Sourced. A note on naming: this series' working company list used the name "Orca Therapeutics", but this article treats Orca Bio (legal name Orca Biosystems, Inc.), the name that appears in company and regulatory documents, as the correct company name Sourced.
2. The logo and how the name is written
A note on names: the company name is Orca Bio, while the U.S. legal entity and the holder of the FDA approval is Orca Biosystems, Inc. We did not find the name "Orca Therapeutics", which appears in this series' working list, in any company, FDA or ClinicalTrials.gov document we checked. The product is named TREGZI (known clinically as Orca-T), and the second-generation candidate is Orca-Q. The logo is the white version of the image in the header of the official website, downloaded and shown here on a dark background; we have not recreated it with generated imagery.
Official site: https://orcabio.com/3. Where the company sits in the iPS cell and regenerative medicine landscape
Seen by mechanism, the core of Orca Bio is engineering the contents of an allogeneic transplant. The issues covered in this series' explainers on autologous versus allogeneic cells, cell manufacturing and cell banks, GMP, expedited pathways for regenerative medicine, and marketing applications and real-world data all appear here.
| Mechanism | How Orca Bio uses it | Category |
|---|---|---|
| Allogeneic (other-person-derived) cell therapy | Three types of cell are sorted from the mobilised peripheral blood of an HLA-matched donor. One lot per patient | Sourced |
| Cell sorting | Haematopoietic stem and progenitor cells (HSPC), regulatory T cells (Treg) and conventional T cells (Tcon) are purified separately and then combined | Sourced |
| Suppressing graft-versus-host disease (GVHD) | A design in which Treg dampen the reaction while Tcon keep immune reconstitution going and the graft-versus-leukaemia (GVL) effect, in which donor cells attack leukaemia cells | Sourced |
| Genome editing and gene transfer | Not used in TREGZI. The company's pipeline table lists a separate OrCAR platform of gene-transferred CAR-T cells, in Phase 1 for B-cell acute lymphoblastic leukaemia and in IND preparation for multiple myeloma | Sourced |
| iPS cells | In what we could confirm, the company's products and research make no mention of iPS cells | Could not be confirmed |
4. Scale (an unlisted company)
Orca Bio is unlisted, and its revenue, R&D spending and profit and loss are not published Not yet confirmed. Its first product was only approved on 30 June 2026, and neither product sales nor price appears in the materials we could confirm.
| Indicator | Value | How the source states it |
|---|---|---|
| Founded | 2016 | Company fact sheet |
| Headquarters / manufacturing sites | Menlo Park (headquarters) / Sacramento (clinical and commercial manufacturing) / Princeton (new East Coast site) | Fact sheet; release of 15 June 2026 |
| Employees | More than 400 | Third-quarter 2026 fact sheet |
| Patients treated in clinical trials | About 600 | Same |
| Funding | US$192 million Series D in 2020 (about US$300 million raised in total). Series F completed in 2026 (no amount stated) | Company timeline; approval announcement |
5. Resources committed to iPS cells and regenerative medicine
We sort four points (people, money, outside investments, acquisitions and in-licensing, and links with universities and public funding) by whether the primary sources let us confirm them.
| Aspect | What the primary sources confirm | Status |
|---|---|---|
| People (sites and headcount) | More than 400 employees. The company says it has more than tripled its Sacramento operations team over the past year. It appointed a chief medical officer in May 2026 | Confirmed |
| Money (R&D spending and manufacturing facilities) | Construction of the Sacramento commercial manufacturing facility began in 2022, with first manufacturing there in 2024. An East Coast manufacturing site has been added in Princeton. The amounts of capital expenditure and R&D spending are not disclosed | Facilities confirmed. Amounts could not be confirmed |
| Outside investments, acquisitions and in-licensing | The Series F was led by Lightspeed Venture Partners. The materials we could confirm do not mention acquisitions of other companies or licence agreements with pharmaceutical companies | Investors confirmed. Partnerships and acquisitions could not be confirmed |
| Universities, research institutions and public funding | Precision-T was run at 19 treatment centres in the United States. One of the founders came from the Weissman laboratory at Stanford University. We could not confirm any university licence or public grant | Sites confirmed. Agreements and grants could not be confirmed |
According to the FDA review summary, TREGZI is a fresh (never frozen) product made as a separate lot for each patient-donor pair. The HSPC and Treg product is stored at 5 ± 3 °C with an expiry of 72 hours from collection, while the conventional T cell product is frozen below −125 °C with an expiry of 7 days from collection Sourced. In other words, sorting, formulation, shipping and administration all have to be finished within 72 hours of collection. From a materials standpoint, cell sorting generally requires reagents such as antibodies, beads, buffers, storage solutions, shipping containers and temperature control, and the quality of these feeds straight into product quality and supply stability (this is our own assumption; the company and FDA documents do not disclose specific materials).
The company's safety information states that the product contains DMSO, human serum albumin, dextran and mouse-derived protein, which means animal-derived reagents are used in its manufacture Sourced. Among its post-marketing commitments (PMCs), the FDA lists a review of the acceptance criteria for critical reagents and raw materials Sourced.
6. Track record so far
| When | What happened | What it means |
|---|---|---|
| 2016 | Orca Bio founded | Started with precision as the watchword for allogeneic cell therapy |
| 2019 | First manufacture of Orca-T at its own GMP clinical facility. IND (application to begin clinical trials) in May 2019. The same year, the first patient was treated with the second-generation Orca-Q | Start of clinical development |
| 2020 | Came out of stealth and raised a US$192 million Series D (about US$300 million in total). Orca-T designated RMAT (30 July) | Funding and expedited-pathway benefits |
| 2021 | Presented results for more than 100 Orca-T patients at ASH (the American Society of Hematology meeting) | Accumulation of Phase 1/2 data |
| 2022 | Began construction of a commercial manufacturing facility in Sacramento. Presented early results for Orca-Q with haploidentical (half-matched) donors | Bringing manufacturing in house |
| 2024 | First manufacture of Orca-T at the commercial facility. Orca-T received orphan drug designation in January | Setting up for approval |
| 2025 | The Phase 3 Precision-T met its primary endpoint and was presented at EBMT. The BLA (Biologics License Application) was submitted in August and accepted in October with priority review (PDUFA target date of 6 April 2026) | Marketing application |
| March to April 2026 | A substantial amount of additional CMC (manufacturing and quality) information was submitted, extending the review by three months (target date 6 July). Orca-Q was designated RMAT in April | Manufacturing became the last hurdle |
| 15 June 2026 | Added an East Coast manufacturing site in Princeton and more than tripled the Sacramento operations team (announced before approval) | Preparing for commercialisation |
| 30 June 2026 | The FDA approved TREGZI (ahead of the target date). Its first approved product | Became a company with an approved product |
7. Plans ahead
The FDA writes that at approval it asked for unresolved issues in manufacturing consistency and test methods to be addressed as post-marketing commitments. Specifically these include evaluating manufacturing consistency at the commercial facility in Sacramento, quarterly reports for two years after approval, and a review of the acceptance criteria for critical reagents Sourced.
None of the following appears in the primary sources Not yet confirmed.
The price and sales of TREGZI / the number of patients that can be manufactured for per year / the amount of the Series F / R&D spending / the specific candidates and timing for autoimmune disease / plans to apply in Japan or Europe. Press-based figures and research-firm estimates are not used in this article.
8. What the company is aiming for in iPS cells and regenerative medicine
This section includes things the company does not say directly. We set them out as inferences within what the primary sources support, with the evidence for each.
| What the evidence suggests | Primary information it rests on | Category |
|---|---|---|
| It aims to replace a diseased blood and immune system with a healthy one | The company says the purpose of its products is to replace the patient's diseased blood and immune system with a healthy one | Sourced |
| After blood cancers, it intends to extend to autoimmune disease | The company's self-description reads "blood cancers and autoimmune diseases". The materials we checked, however, name no specific autoimmune candidate | Sourced |
| It is also taking in gene-transferred cells such as CAR-T | The pipeline has the OrCAR platform (Phase 1 in B-cell acute lymphoblastic leukaemia; IND preparation in multiple myeloma) | Sourced |
| Speed and volume of supply will limit its growth | The product is fresh and donor-dependent. The company stresses the new East Coast site and closer ties with donor registries, and the FDA also raised manufacturing consistency as an issue | Inference |
| It has chosen commercialising on its own over partnering with pharma | The materials we could confirm contain no licensing or co-development with pharmaceutical companies. The company calls itself a "commercial-stage company" | Inference |
The FDA review summary repeatedly describes TREGZI as a fresh product, matched to the donor, with one lot per patient, and treats this as a difficulty for the review. The expiry is short, at 72 hours from collection for the HSPC and Treg product, and the product is released on a provisional sterility result, with the final sterility result coming after administration Sourced. For this reason we read the thing that will decide how far the product spreads as less demand than how far the company can grow the manufacturing and logistics network that fits collection, sorting and shipping into 72 hours. The company's adding an East Coast site and tripling its operations team even before approval looks like a response to this constraint, but the company has not explained it that way Inference.
9. Partnership map for iPS cells and regenerative medicine
What stands out about Orca Bio is that it has no partnership with a large pharmaceutical company and keeps manufacturing in house. It raises money from investors (Lightspeed and others) and runs its trials jointly with treatment centres in the United States Sourced. Where many cell therapy companies rely on contract manufacturers (CDMOs) or pharmaceutical partners for manufacturing, we characterise Orca Bio as vertically integrated, with manufacturing at its core Inference.
10. The technologies and products it offers
TREGZI was approved by the FDA on 30 June 2026. The other candidates in the table below are unapproved investigational products.
| Candidate | Description and target | Stage (trial name, NCT number) | Primary endpoint |
|---|---|---|---|
| TREGZI (Orca-T) | A combination of HSPC, Treg and Tcon. For adults with blood cancers undergoing haematopoietic stem cell transplant from a matched donor after myeloablative conditioning | Approved (U.S., 30 June 2026; BLA 125868; orphan drug, RMAT and priority review). Precision-T, NCT05316701 (Phase 3) | Survival free of moderate-to-severe chronic GVHD (cGFS) |
| Orca-Q | Second generation. Includes haploidentical (half-matched) and mismatched donors | In development (Phase 1). NCT03802695. RMAT designation in April 2026. Estimated enrolment of 300 | Dose-limiting toxicity; primary graft failure |
| OrCAR platform | Gene-transferred CAR-T cells (B-cell acute lymphoblastic leukaemia, multiple myeloma) | Preclinical to Phase 1 (company pipeline table) | - |
The results that supported approval are shown below. The comparator is a conventional transplant (tacrolimus plus methotrexate), not a comparison with other prophylaxis methods.
| Measure | TREGZI arm | Control arm (conventional transplant) | Time point and conditions |
|---|---|---|---|
| Survival free of chronic GVHD (primary endpoint) | 78.0% | 38.4% | 12 months. Hazard ratio 0.26 (95% confidence interval 0.14 to 0.47). Median follow-up as assessed by the FDA of about 8.5 months and about 9.0 months |
| Moderate-to-severe chronic GVHD | 12.6% | 44.0% | Cumulative incidence at 12 months |
| Overall survival | 93.9% | 83.1% | 12 months. The difference is not statistically significant (P=0.12). The FDA records no significant difference at the interim analysis |
| Survival free of relapse and GVHD | 63.1% | 30.9% | 12 months. The FDA did not test it, because overall survival was not significant |
| Non-relapse mortality | 3.4% | 13.2% | 12 months (P=0.03) |
The study was an open-label, randomised trial of 187 people (93 in the TREGZI arm and 94 in the control arm) at 19 sites in the United States Sourced.
According to the FDA review summary, quality control consists of incoming evaluation of raw materials and reagents, in-process monitoring, lot-release testing, process validation, and chain of identity / chain of custody (tracking that makes sure one person's cells are never mixed up with another's) Sourced. A potency assay for the Treg was adopted for lot release while acknowledging its limitations, and a specific marker identifying Treg was left out of the release criteria because of logistical constraints. The product is also released on a rapid microbiological test rather than waiting for the final sterility result. This shows a regulatory compromise for a live-cell product under severe time constraints, and further validation of the test methods is required after approval (our reading).
11. The risks this company carries
| Risk | Details | Category |
|---|---|---|
| Manufacturing consistency | FDA review raised major issues on test methods, manufacturing consistency and donor eligibility, and the review was extended. Additional post-approval commitments were imposed | Sourced |
| Short follow-up | Median follow-up for the main results is about 9 months. Overall survival was not significantly different at the interim analysis, and longer-term outcomes remain to be confirmed | Sourced |
| Limited population | The approved use is for adults undergoing a transplant from a matched donor after myeloablative conditioning. The control was conventional prophylaxis (tacrolimus plus methotrexate) | Sourced |
| Logistics of a fresh product | Cells must be sorted and administered within 72 hours of collection, which presupposes expanding the sites and logistics network | Sourced |
| Safety precautions | The prescribing information carries precautions on graft failure, GVHD, infusion reactions, secondary and donor-derived cancers, and transmission of infection | Sourced |
| An unlisted company with limited information | Revenue, costs and cash cannot be verified from outside | Not yet confirmed |
| Competing prophylaxis methods | There are other ways to prevent GVHD, and a direct randomised comparison with them was not part of the basis for this approval | Sourced |
12. Glossary
- Allogeneic haematopoietic stem cell transplant
- A treatment in which haematopoietic stem cells from another person (a donor) are transplanted. It aims at a cure for blood cancers but carries complications such as GVHD.
- GVHD
- Graft-versus-host disease. A reaction in which the donor's immune cells attack the patient's body.
- Regulatory T cell (Treg)
- A T cell that suppresses immune reactions. Used in TREGZI to hold GVHD in check.
- HSPC
- Haematopoietic stem and progenitor cells. The cells that rebuild the blood and immune system.
- GVL
- Graft-versus-leukaemia effect. The action of the donor's immune cells in attacking cancer cells.
- cGFS
- Survival free of chronic GVHD. The primary endpoint of Precision-T.
- RMAT
- Regenerative Medicine Advanced Therapy. An FDA programme that speeds up the development and review of regenerative medicine products. Designation does not mean approval.
- PMC
- Post-marketing commitment. Further validation of manufacturing or test methods that the FDA asks for as a condition of approval.
- Vein-to-vein time
- The time from collection (from the vein of the patient or donor) to administration to the patient.
- PDUFA
- The system under which the FDA sets a target date for completing its review.
13. References
- U.S. FDA (CBER) TREGZI product approval information page. Manufacturer and approval documents (approval letter dated 1 July 2026; review summary dated 30 June 2026). https://www.fda.gov/vaccines-blood-biologics/tregzi
- U.S. FDA Summary Basis for Regulatory Action (TREGZI, 30 June 2026). History of the review, efficacy, CMC issues and post-approval commitments. https://www.fda.gov/media/193956/download?attachment
- U.S. FDA FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq (explanatory page on the approval). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-allogeneic-regulatory-t-cell-based-immunotherapy-hspc-and-t-cells-vldq-use-matched
- Orca Bio Orca Bio’s TREGZI Receives U.S. FDA Approval (30 June 2026). Indication, Precision-T results, safety information and company overview. https://orcabio.com/orca-bios-tregzi-receives-u-s-fda-approval-as-first-and-only-precision-engineered-cell-therapy-for-allogeneic-transplant-in-adults-with-hematological-malignanciesorca-bio-adds-east/
- Orca Bio Orca Bio Corporate Overview (fact sheet for the third quarter of 2026). Year founded, sites, headcount and number of patients treated. https://orcabio.com/wp-content/uploads/2026/08/OrcaBioFactSheetQ32026.pdf
- Orca Bio Orca Bio Adds East Coast Manufacturing Capacity and Triples West Coast Manufacturing Workforce (15 June 2026). https://orcabio.com/orca-bio-adds-east-coast-manufacturing-capacity-and-triples-west-coast-manufacturing-workforce-ahead-of-potential-orca-t-launch/
- Orca Bio Orca-Q RMAT designation (28 April 2026). The second-generation candidate. https://orcabio.com/orca-bio-announces-u-s-fda-regenerative-medicine-advanced-therapy-rmat-designation-granted-to-orca-q-for-the-treatment-of-high-risk-hematologic-malignancies/
- Orca Bio FDA Review Extension of BLA for Orca-T (1 April 2026). https://orcabio.com/orca-bio-announces-fda-review-extension-of-bla-for-orca-t-for-the-treatment-of-hematologic-malignancies/
- Orca Bio Company information page (year founded, timeline, management). https://orcabio.com/our-company/
- Orca Bio Pipeline page (Orca-T, Orca-Q and the OrCAR platform). https://orcabio.com/our-pipeline/
- Peer-reviewed paper Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood 2026 (PMID 41385341). https://doi.org/10.1182/blood.2025031313
- ClinicalTrials.gov NCT05316701 (Precision-T: Phase 3 of Orca-T). https://clinicaltrials.gov/study/NCT05316701
- ClinicalTrials.gov NCT03802695 (Phase 1 of Orca-Q). https://clinicaltrials.gov/study/NCT03802695
14. Claim-to-source audit
Last updated 1 October 2026 / Troy Technical
Every figure in this article comes from the FDA, Orca Bio's official announcements, a peer-reviewed paper (Blood) and ClinicalTrials.gov registrations. No research-firm estimates or press-based figures have been used. Passages marked "Inference" are this article's interpretation of the primary sources, not statements made by the company. This article is not medical advice, does not recommend any particular treatment or product, and makes no comparison of its merits with other treatments.